1.
Li GX, Chen L, Hsiao Y, et al. Comprehensive proteogenomic characterization of rare kidney tumors. Cell reports. Medicine. 2024:101547. doi:10.1016/j.xcrm.2024.101547.
1.
Petralia F, Ma W, Yaron TM, et al. Pan-cancer proteogenomics characterization of tumor immunity. Cell. 2024. doi:10.1016/j.cell.2024.01.027.
1.
Li Y, Lih T-SM, Dhanasekaran SM, et al. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer cell. 2023;41(1):139-163.e17. doi:10.1016/j.ccell.2022.12.001.
1.
Li Y, Porta-Pardo E, Tokheim C, et al. Pan-cancer proteogenomics connects oncogenic drivers to functional states. Cell. 2023. doi:10.1016/j.cell.2023.07.014.
1.
Li Y, Dou Y, Leprevost F da V, et al. Proteogenomic data and resources for pan-cancer analysis. Cancer cell. 2023;41(8):1397-1406. doi:10.1016/j.ccell.2023.06.009.
1.
Dou Y, Katsnelson L, Gritsenko MA, et al. Proteogenomic insights suggest druggable pathways in endometrial carcinoma. Cancer cell. 2023. doi:10.1016/j.ccell.2023.07.007.
1.
Xu J, Kong L, Oliver BA, et al. Constitutively active autophagy in macrophages dampens inflammation through metabolic and post-transcriptional regulation of cytokine production. Cell reports. 2023;42(7):112708. doi:10.1016/j.celrep.2023.112708.
1.
Anurag M, Jaehnig EJ, Krug K, et al. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022;12(11):2586-2605. doi:10.1158/2159-8290.CD-22-0200.
1.
Zhang Y, Ng PK-S, Kucherlapati M, et al. A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell. 2017;31(6):820-832.e3. doi:10.1016/j.ccell.2017.04.013.
1.
Ruggles KV, Krug K, Wang X, et al. Methods, Tools and Current Perspectives in Proteogenomics. Mol Cell Proteomics. 2017;16(6):959-981. doi:10.1074/mcp.MR117.000024.